Blood cancer can be fatal if not detected early; innovative biosensors with machine learning optimization enable timely diagnosis by identifying cancer-specific biomarkers in blood, improving survival ...

Therapeutic advances have improved cancer outcomes, but early-stage detection remains the single most important determinant of favorable prognoses across many cancer types. Cancer genomics has yielded ...

A four-biomarker blood panel of aminopeptidase N (ANPEP), polymeric immunoglobulin receptor (PIGR), CA19-9, and thrombospondin-2 (THBS2) enhanced the detection of pancreatic ductal adenocarcinoma ...

Use of tumor-intrinsic pathways to identify novel targets in immune-cold esophagogastric adenocarcinoma. Determinants of biomarker testing and treatment selection by oncologists caring for patients ...

A multicancer early detection (MCED) test was developed and validated in the case-control Circulating Cell-free Genome Atlas (CCGA) study (ClinicalTrials.gov identifier: NCT02889978). Previous ...

The prospect of diagnosing cancer through painless methods—such as a simple AI-assisted blood or urine test that detects tiny particles known as exosomes—is becoming increasingly realistic. Scientists ...

A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNA nanotechnology, ...

A Chinese research team has developed the world's first blood-based diagnostic kit that can tell whether lung nodules are benign or cancerous, including very small nodules that are often difficult to ...

The tests have not been approved by federal regulators, but that hasn’t stopped patients from wanting them — and doctors from worrying. By Nina Agrawal In the spring of 2021, the cancer field was ...

GRAIL IS AN American biotech company with an ambitious goal: to develop a blood test for the early detection of over 50 types of cancer. It will not be easy. On February 19th the company announced ...

Multicancer blood tests have for years been hyped as a potential breakthrough in early cancer detection. But with news that one of the big names in the field, the Galleri test, failed to meet its ...